IDEAYA reports Q3 net loss of $51.8M; cash $1.2B; progress in darovasertib and IDE397 trials

IDEAYA Biosciences, Inc.

2024-Q3 EPS reported -$1.81

Net loss of $51.8M for Q3 2024; R&D expenses $57.2M; G&A $9.7M.
Cash, equivalents and marketable securities of $1.2B as of Sep 30, 2024, up from $952.7M due to $283.8M follow-on net proceeds.
Darovasertib + crizotinib 1L UM registration trial enrollment exceeded 150 patients; successful FDA Type C meeting for neoadjuvant Ph3 targeting H1 2025 initiation.
IDE397 Phase 1 expansion at ENA 2024 showed 40% confirmed ORR in MTAP-deletion UC, 38% in squamous NSCLC, and 22% in adeno NSCLC.
IND clearance for IDE275 (Werner helicase) earned $7M milestone from GSK; targeting 3 DC nominations in Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.